Chakraborty R, Riaz IB, Malik SU, et al. - By analyzing evidence from relevant phase 1, 2, and 3 clinical trials identified from Ovid MEDLINE, Embase, and Cochrane databases, researchers estimated the incidence of venous thromboembolism (VTE) among patients with myeloma who have already received thromboprophylaxis with currently used lenalidomide-based regimens. The included studies were those that assessed lenalidomide-based regimens with thromboprophylaxis. Overall 1,372 citations were identified, including 51 clinical trials and 9,069 patients examined. Aspirin, low-molecular-weight heparin or warfarin constituted the most commonly used thromboprophylaxis agents. In trials involving patients who had newly diagnosed and relapsed/refractory myeloma, the pooled incidence of VTE was estimated to be 6.2% over median treatment durations ranging from 2 to 34 cycles, which translated into 1.2 VTE events per 100 patient-cycles. Overall, a substantial risk of VTE associated with lenalidomide-based regimens was evident in controlled clinical trial settings, despite adequate thromboprophylaxis.